Abstract
Live attenuated influenza vaccines (LAIVs) provide robust, cross-protective immunity but have traditionally been developed empirically and are associated with safety concerns. Recent advances in rational design enable precise genetic modifications to enhance safety and immunogenicity. This review highlights key molecular strategies advancing next-generation LAIV development and their potential to accelerate the production of safer, more effective vaccines against seasonal and pandemic influenza.